ACXP logo

Acurx Pharmaceuticals (ACXP) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

25 June 2021

Indexes:

Not included

Description:

Acurx Pharmaceuticals (ACXP) focuses on developing innovative antibiotics to treat serious bacterial infections. The company aims to address the growing problem of antibiotic resistance with its unique drug candidates, offering new solutions for patients and healthcare providers.

Events Calendar

Earnings

Next earnings date:

Mar 18, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

Mar 18, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

14 Nov '24 HC Wainwright & Co.
Buy
12 Aug '24 HC Wainwright & Co.
Buy
16 May '24 HC Wainwright & Co.
Buy
19 Mar '24 HC Wainwright & Co.
Buy
28 Feb '24 HC Wainwright & Co.
Buy
15 Dec '23 HC Wainwright & Co.
Buy
15 Nov '23 HC Wainwright & Co.
Buy
13 Sept '23 HC Wainwright & Co.
Buy
15 Aug '23 HC Wainwright & Co.
Buy
15 May '23 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Here's Why Acurx Pharmaceuticals (ACXP) Is a Great 'Buy the Bottom' Stock Now
Here's Why Acurx Pharmaceuticals (ACXP) Is a Great 'Buy the Bottom' Stock Now
Here's Why Acurx Pharmaceuticals (ACXP) Is a Great 'Buy the Bottom' Stock Now
ACXP
zacks.com28 November 2024

Acurx Pharmaceuticals (ACXP) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Transcript
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Transcript
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Transcript
ACXP
seekingalpha.com13 November 2024

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Robert Shawah - Co-Founder & CFO David Luci - Co-Founder, President, CEO, Corporate Secretary & Director Conference Call Participants Thomas Yip - H.C. Wainwright John Stinson - Private Investor Operator Greetings, and welcome to the Acurx Pharmaceuticals, Inc. Third Quarter 2024 Results and Business Update Conference Call.

Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference
Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference
Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference
ACXP
prnewswire.com21 October 2024

The data presented indicate a favorable gut bile acid profile which may contribute to ibezapostat's beneficial anti-recurrence effect in patients with C. difficile Infection (CDI) Ibezapolstat treatment of patients with CDI is associated with the restoration of beneficial bacterial classes in the gut Preparation continues to advance ibezapolstat into international Phase 3 clinical trials for treatment of C.

Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024
Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024
Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024
ACXP
prnewswire.com16 October 2024

STATEN ISLAND, N.Y. , Oct. 16, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late- stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its third quarter 2024 financial results on Wednesday, November 13, 2024 at 8:00 am ET before the U.S. financial markets open.

New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support
New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support
New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support
ACXP
accesswire.com14 October 2024

The new series features continued broadcast television interviews, earned media placements, and a comprehensive outdoor advertising campaign. NEW YORK, NY / ACCESSWIRE / October 14, 2024 / New to The Street, one of the leading U.S. business television platforms, is pleased to announce the renewal of its media partnership with Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP), a late-stage biopharmaceutical company.

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update
ACXP
prnewswire.com09 August 2024

STATEN ISLAND, N.Y. , Aug. 9, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended June 30, 2024.

Acurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call Transcript
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call Transcript
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call Transcript
ACXP
Seeking Alpha18 March 2024

Acurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call Transcript

Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update
Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update
Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update
ACXP
PRNewsWire04 March 2024

STATEN ISLAND, N.Y. , March 4, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its fourth quarter and full year 2023 financial results on Monday, March 18, 2024, at 8:00 am ET before the U.S. financial markets open.

Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024
Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024
Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024
ACXP
PRNewsWire23 January 2024

STATEN ISLAND, N.Y. , Jan. 23, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company") (NASDAQ: "ACXP"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that David P.

Acurx Sell-Off Presents Opportunity Before Upcoming Data Release
Acurx Sell-Off Presents Opportunity Before Upcoming Data Release
Acurx Sell-Off Presents Opportunity Before Upcoming Data Release
ACXP
Seeking Alpha22 January 2024

Acurx shares opened ~25% lower on Jan 17th, after releasing positive data suggesting its C. diff antibiotic outperformed standard treatment in restoring the gut microbiome. The decline in share price since then may be due to misaligned investor expectations regarding the release of sustained clinical cure rates. Acurx is expected to release additional data, including 94-day sustained clinical cure rates, which could further establish its antibiotic as a preferred treatment for C. diff.

FAQ

  • What is the primary business of Acurx Pharmaceuticals?
  • What is the ticker symbol for Acurx Pharmaceuticals?
  • Does Acurx Pharmaceuticals pay dividends?
  • What sector is Acurx Pharmaceuticals in?
  • What industry is Acurx Pharmaceuticals in?
  • What country is Acurx Pharmaceuticals based in?
  • When did Acurx Pharmaceuticals go public?
  • Is Acurx Pharmaceuticals in the S&P 500?
  • Is Acurx Pharmaceuticals in the NASDAQ 100?
  • Is Acurx Pharmaceuticals in the Dow Jones?
  • When was Acurx Pharmaceuticals's last earnings report?
  • When does Acurx Pharmaceuticals report earnings?
  • Should I buy Acurx Pharmaceuticals stock now?

What is the primary business of Acurx Pharmaceuticals?

Acurx Pharmaceuticals (ACXP) focuses on developing innovative antibiotics to treat serious bacterial infections. The company aims to address the growing problem of antibiotic resistance with its unique drug candidates, offering new solutions for patients and healthcare providers.

What is the ticker symbol for Acurx Pharmaceuticals?

The ticker symbol for Acurx Pharmaceuticals is NASDAQ:ACXP

Does Acurx Pharmaceuticals pay dividends?

No, Acurx Pharmaceuticals does not pay dividends

What sector is Acurx Pharmaceuticals in?

Acurx Pharmaceuticals is in the Healthcare sector

What industry is Acurx Pharmaceuticals in?

Acurx Pharmaceuticals is in the Biotechnology industry

What country is Acurx Pharmaceuticals based in?

Acurx Pharmaceuticals is headquartered in United States

When did Acurx Pharmaceuticals go public?

Acurx Pharmaceuticals's initial public offering (IPO) was on 25 June 2021

Is Acurx Pharmaceuticals in the S&P 500?

No, Acurx Pharmaceuticals is not included in the S&P 500 index

Is Acurx Pharmaceuticals in the NASDAQ 100?

No, Acurx Pharmaceuticals is not included in the NASDAQ 100 index

Is Acurx Pharmaceuticals in the Dow Jones?

No, Acurx Pharmaceuticals is not included in the Dow Jones index

When was Acurx Pharmaceuticals's last earnings report?

Acurx Pharmaceuticals's most recent earnings report was on 13 November 2024

When does Acurx Pharmaceuticals report earnings?

The next expected earnings date for Acurx Pharmaceuticals is 18 March 2025

Should I buy Acurx Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions